𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

✍ Scribed by Maha M. T. El-Zimaity; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Srdan Verstovsek; Deborah Thomas; Alessandra Ferrajoli; Kimberly Hayes; B. Nebiyou Bekele; Xian Zhou; Mary B. Rios; Armand B. Glassman; Jorge E. Cortes

Book ID
108672587
Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
134 KB
Volume
125
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chromosomal abnormalities in Philadelphi
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
✍ Jorge Medina; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Ma 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract ## BACKGROUND Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome (Ph)‐negative metaphases have been reported in patients with chronic myelogenous leukemia (CML) in the chronic phase during treatment with interferon and, more recently, with imatinib. This phenomenon

Outcome of patients with Philadelphia ch
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
✍ Hagop Kantarjian; Susan O'Brien; Moshe Talpaz; Gautam Borthakur; Farhad Ravandi; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 1 views

## Abstract ## BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. ## METHODS. The outcome of 420 patients with CML post‐imatinib failure (resistance‐recurrence in 374; toxicities in 46) were reviewed in

Effects of age on prognosis with imatini
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
✍ Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Jianqu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 1 views

## Abstract ## BACKGROUND Older age is a consistent poor prognostic factor in patients with Philadelphia chromosome (Ph)‐positive chronic myelogenous leukemia (CML). Whether this is related to an intrinsic worse disease biology or to inadequate drug delivery or excessive treatment‐associated toxic

Imatinib mesylate therapy improves survi
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase : Comparison with historic data
✍ Hagop M. Kantarjian; Susan O'Brien; Jorge Cortes; Francis J. Giles; Mary Beth Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract ## BACKGROUND The International Randomized study of Interferon‐alpha plus cytarabine (IFN‐α plus ara‐C) versus STI571 (imatinib mesylate) [IRIS trial] in patients with newly diagnosed Philadelphia chromosome (Ph)‐positive, chronic‐phase chronic myelogenous leukemia (CML) has not shown